EQT to acquire Qiagen in €10.8 billion deal

EQT, a private‑equity firm, announced it will purchase Dutch molecular diagnostics company Qiagen in a transaction valued at €10.8 billion, including €1.1 billion of net debt.

The deal follows a failed attempt by Thermo Fisher six years earlier to buy Qiagen for about $12.5 billion, which was blocked by shareholders. Qiagen’s board now supports the sale and its shares rose on the news.

Qiagen’s new CEO Jonathan M. Pratt, appointed two months ago after Thierry Bernard’s departure, said private ownership will give the company flexibility to invest for long‑term growth.

The acquisition adds to a recent wave of med‑tech transactions, underscoring continued consolidation in the sector.